Polypharmacy Associated with Cognitive Decline in Newly Diagnosed Parkinson's Disease: A Cross-Sectional Study.

IF 1.4 Q4 CLINICAL NEUROLOGY

Dementia and Geriatric Cognitive Disorders Extra Pub Date : 2019-09-10 eCollection Date: 2019-09-01 DOI:10.1159/000502351

Nobuyuki Ishii, Hitoshi Mochizuki, Katsuya Sakai, Go Ogawa, Kazutaka Shiomi, Masamitsu Nakazato

{"title":"Polypharmacy Associated with Cognitive Decline in Newly Diagnosed Parkinson's Disease: A Cross-Sectional Study.","authors":"Nobuyuki Ishii, Hitoshi Mochizuki, Katsuya Sakai, Go Ogawa, Kazutaka Shiomi, Masamitsu Nakazato","doi":"10.1159/000502351","DOIUrl":null,"url":null,"abstract":"Aims: Polypharmacy is well known to affect cognitive function in community-dwelling older adults. However, the effect of polypharmacy on cognitive function in patients with newly diagnosed Parkinson's disease remains unknown. Here, we evaluated the association between polypharmacy and cognitive function in patients with newly diagnosed Parkinson's disease.Methods: This cross-sectional study enrolled 131 consecutive hospitalized patients with newly diagnosed Parkinson's disease. Cognitive function was evaluated with the Mini-Mental State Examination and analyzed between groups of patients with or without polypharmacy. Comparisons were adjusted for confounders by performing inverse probability weighting with propensity scores.Results: After inverse probability weighting, patients in the polypharmacy group had a significantly lower Mini-Mental State Examination score than patients in the nonpolypharmacy group (26.2 vs. 27.7, p = 0.001).Conclusion: Polypharmacy was associated with cognitive decline in patients with newly diagnosed Parkinson's disease. This finding suggests that medication reduction might serve as a promising intervention to prevent the development of dementia in patients with early Parkinson's disease. Further prospective studies are needed to determine whether medication reduction improves cognitive function in patients with newly diagnosed Parkinson's disease.","PeriodicalId":38017,"journal":{"name":"Dementia and Geriatric Cognitive Disorders Extra","volume":"9 3","pages":"338-343"},"PeriodicalIF":1.4000,"publicationDate":"2019-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000502351","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders Extra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000502351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 12

Abstract

Aims: Polypharmacy is well known to affect cognitive function in community-dwelling older adults. However, the effect of polypharmacy on cognitive function in patients with newly diagnosed Parkinson's disease remains unknown. Here, we evaluated the association between polypharmacy and cognitive function in patients with newly diagnosed Parkinson's disease.

Methods: This cross-sectional study enrolled 131 consecutive hospitalized patients with newly diagnosed Parkinson's disease. Cognitive function was evaluated with the Mini-Mental State Examination and analyzed between groups of patients with or without polypharmacy. Comparisons were adjusted for confounders by performing inverse probability weighting with propensity scores.

Results: After inverse probability weighting, patients in the polypharmacy group had a significantly lower Mini-Mental State Examination score than patients in the nonpolypharmacy group (26.2 vs. 27.7, p = 0.001).

Conclusion: Polypharmacy was associated with cognitive decline in patients with newly diagnosed Parkinson's disease. This finding suggests that medication reduction might serve as a promising intervention to prevent the development of dementia in patients with early Parkinson's disease. Further prospective studies are needed to determine whether medication reduction improves cognitive function in patients with newly diagnosed Parkinson's disease.

查看原文本刊更多论文

新诊断帕金森病患者认知能力下降的多药治疗：一项横断面研究。

目的：众所周知，多药治疗会影响社区老年人的认知功能。然而，多药治疗对新诊断的帕金森病患者认知功能的影响仍然未知。在这里，我们评估了新诊断的帕金森病患者的多药治疗与认知功能之间的关系。方法：这项横断面研究纳入了131名连续住院的新诊断帕金森病患者。认知功能通过迷你精神状态检查进行评估，并在使用或不使用多种药物的患者组之间进行分析。通过对倾向得分进行反向概率加权，对混杂因素进行比较调整。结果：经过逆概率加权后，多药治疗组的患者的迷你精神状态检查得分显著低于非多药组（26.2比27.7，p=0.001）。结论：多药治疗与新诊断的帕金森病患者的认知能力下降有关。这一发现表明，减少药物治疗可能是一种很有前途的干预措施，可以预防早期帕金森病患者患痴呆症。需要进一步的前瞻性研究来确定减少药物治疗是否能改善新诊断的帕金森病患者的认知功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dementia and Geriatric Cognitive Disorders Extra Medicine-Psychiatry and Mental Health

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： This open access and online-only journal publishes original articles covering the entire spectrum of cognitive dysfunction such as Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field. Dementia and Geriatric Cognitive Disorders Extra provides additional contents based on reviewed and accepted submissions to the main journal Dementia and Geriatric Cognitive Disorders Extra .